<DOC>
	<DOCNO>NCT01380275</DOCNO>
	<brief_summary>The purpose study estimate control rate ( CR , PR , SD ) docetaxel irinotecan ( DI ) combination chemotherapy recurrent refractory bone soft tissue sarcomas.Al , study evaluate toxicity profile Docetaxel Irinotecan ( DI ) combination chemotherapy .</brief_summary>
	<brief_title>Trial Docetaxel Irinotecan ( DI ) Recurrent Refractory Bone Soft Tissue Sarcomas .</brief_title>
	<detailed_description>Treatment setting : Hospitalization prefer , treatment outpatient base allow . Regimen premedication 1 . Regimen Docetaxel 100 mg/m2 mixed D5W N/S IV 60 min : Day 1 Irinotecan 80 mg/m2 mixed D5W IV 90 min : Days 1 8 2 . Premedications Dexamethasone 3 mg/m2 PO IV 12 hour 1 hour prior docetaxel administration . A third dose dexamethasone give 8 hour follow docetaxel infusion . Patients treat docetaxel start PO premedication previous day . Parenteral pheniramine maleate may give prior docetaxel patient previous hypersensitivity agent . If use , pheniramine maleate ( 1 mg/kg IV ) administer 30 minute prior infusion every six hour thereafter , need . Treatment interval overall treatment period : Therapy consist 3-week cycle comprise weekly treatment 2 week ( docetaxel D1 irinotecan D1 D8 ) follow 1-week rest , continue absence disease progression unacceptable toxicity . Maximal number cycle twelve , however , additional cycle may employ least PR maintain patient want take . Treatment modification : Toxicity evaluate accord common terminology criterion adverse event v3.0 ( CTCAE ) National Cancer Institute . Next cycle delay ANC count start day schedule treatment least 750/μL platelet count least 75,000/μL , full dos irinotecan docetaxel give . Next cycle also delay diarrhea grade 2 high ( include moderate cramping ) occur day dose due . Irinotecan treatment D8 delay D10 grade 2 high non-hematological toxicity occur day dose due . Irinotecan schedule D8 omit diarrhea grade 2 high occur D10 . Doses docetaxel irinotecan subsequent cycle reduce 20 % febrile grade 4 neutropenia ( ANC &lt; 500/μL ) . Subsequent dose reduce 20 % recurrent toxicity . G-CSF allow clinically indicate accord ASCO guideline ( 22 ) . Dose docetaxel subsequent cycle reduce 20 % grade 2 neurologic toxicity/recurrent fluid retention , grade 3 non-hematologic toxicity , include hepatotoxicity , peripheral neuropathy , stomatitis , skin eruption , myalgia , cardiac event , hypersensitivity . Subsequent dose reduce 20 % recurrent toxicity . In patient grade 2 high fluid retention syndrome , prophylactic dexamethasone give 6 mg/m2 bid 3 day . Dose re-escalation dose reduction permit . Docetaxel Irinotecan ( DI ) treatment discontinue patient grade 4 non-hematological toxicity discretion investigator . Dose modification schedule : Docetaxel Irinotecan ( DI ) dose adjustment within cycle make follow guideline show Table 1 2 base weekly WBC count criterion adverse event v3.0 ( CTCAE ) .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>1 . Histologic diagnosis rhabdomyosarcoma , liposarcoma , leiomyosarcoma , malignant fibrous histiocytoma , angiosarcoma , fibrosarcoma , malignant hemangiopericytoma , desmoplastic small round cell tumor , epitheloid sarcoma , clear cell sarcoma , synovial sarcoma , extraskeletal chondrosarcoma , alveolar soft part sarcoma , sarcoma otherwise specify , malignant peripheral nerve sheath tumor , osteogenic sarcoma , Ewing 's sarcoma/PPNET 2 . One prior chemotherapy : Refractory tumor define nonresponsiveness one two regimen . In child le 18 year , ifosfamide/carboplatin/etoposide ( ICE ) VICE ( vincristine + ICE ) chemotherapy recommend prior salvage regimen mandatory . 3 . Nonresectable recurrent refractory rhabdomyosarcoma , liposarcoma , leiomyosarcoma , malignant fibrous histiocytoma , angiosarcoma , fibrosarcoma , malignant hemangiopericytoma , desmoplastic small round cell tumor , epitheloid sarcoma , clear cell sarcoma , synovial sarcoma , extraskeletal chondrosarcoma , alveolar soft part sarcoma , sarcoma otherwise specify , malignant peripheral nerve sheath tumor , osteogenic sarcoma , Ewing 's sarcoma/PPNET 4 . Debulking surgery nonresectable tumor allow remained mass postdebulking measurable enough evaluate response DI . 5 . Disease status must measurable disease define : Lesions accurately measure least one dimension long diameter &gt; 20mm use conventional technique &gt; 10mm spiral CT scan . 6 . Age le 50 year 7 . Predicted life expectancy 8 week 8 . Performance status : ECOG 02 Karnofsky ≥ 50 % patient 10 year age , Lansky ≥ 50 % child equal less 10 year age . 9 . Adequate major organ function define ; Hematopoietic function : ANC &gt; 750/μL , platelet count &gt; 75,000/μL ( If peripheral blood count inadequate due bone marrow infiltration , follow bone marrow biopsy document disease , patient eligible study , inevaluable hematological toxicity . Patients increase infiltration marrow followup marrow exam may receive therapy inadequate blood count recover nonhematologic toxicity . ) Hepatic function : bilirubin &lt; 1.5 mg/dL , AST/ALT level &lt; 2.5 X UNL Renal function : creatinine &lt; 1.5 X UNL age ( Table 3 ) GFR ≥ 50 ml/min/1.73m2 10 . Patients must receive anticancer agent investigational agent course investigation within 3 week prior study entry . At least 8 week must elapse since administration extend radiotherapy nitrosurea . Evaluable lesion must radiotherapy within 8 week start protocol . Previously irradiated lesion use evaluate tumor response must show evidence interim increase size . For patient stem cell transplant , must evidence stable engraftment without need significant blood product support cytokine therapy . 11 . Patients and/or parent legal guardian sign write informed consent . 1 . Patients receive either prior docetaxel irinotecan . 2 . Patients take anticonvulsant . 3 . Patients uncontrolled infection . 4 . Women childbearing age must pregnant lactating . 5 . Inadequate cardiovascular function 6 . Other malignancy within past 3 year except nonmelanomatous skin cancer carcinoma situ cervix 7 . Psychiatric disorder would preclude compliance</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>recurrent , refractory , bone , soft tissue , sarcoma</keyword>
</DOC>